Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05794880 · ClinicalTrials.gov registry record · NA

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

A NA study of Leukemia and Burkitt Lymphoma, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05794880 is a NA study of Leukemia and Burkitt Lymphoma that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 40 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05794880, a NA study of Leukemia and Burkitt Lymphoma, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Interventions

  • DEVICE Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Study Locations (1)

Wisconsin

  • Children's Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-05-01
Est. Completion 2032-05
Phase NA

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT05794880

The ClinicalTrials.gov registry entry for NCT05794880 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (92% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) is the first listed.

NCT05794880 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT05794880 about?

NCT05794880 is a clinical study titled "MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing". This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study...

What is the current status of trial NCT05794880?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2023-05-01. Estimated completion is 2032-05.

What conditions does trial NCT05794880 study?

This clinical trial studies the following conditions: Leukemia, Burkitt Lymphoma, Lymphoblastic Lymphoma, Myelodysplasia, Acute Myeloid Leukemia in Remission.

What interventions are being tested in trial NCT05794880?

The interventions under investigation include: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) (DEVICE).

Who is sponsoring clinical trial NCT05794880?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05794880 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.